Marshall Wace, LLP Ocugen, Inc. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.82 - $1.33 $31,373 - $50,885	38,260 New	38,260 $32,000
Q2 2022 Aug 15, 2022	SELL	$1.83 - $3.45 $230,711 - $434,948	-126,072 Reduced 77.08%	37,483 $85,000
Q1 2022 May 16, 2022	SELL	$2.34 - $4.72 $66,900 - $134,944	-28,590 Reduced 14.88%	163,555 $540,000
Q2 2021 Aug 13, 2021	BUY	$5.52 - $15.68 $1.06 Million - $3.01 Million	192,145 New	192,145 $1.54 Million

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.